Idenix Pharmaceuticals Inc (IDIX)

24.50
0.05 0.20
Prev Close 24.45
Open 24.49
Day Low/High 24.46 / 24.50
52 Wk Low/High 2.93 / 24.50
Volume 5.09M
Avg Volume 2.96M
Exchange
Shares Outstanding 151.50M
Market Cap 3.71B
EPS -0.91
Div & Yield N.A. (N.A)
HCV Players Moving After Merck Buys Idenix

HCV Players Moving After Merck Buys Idenix

Shares of several companies that have developed hepatitis C, or HCV, treatments are rising after one such company, Idenix, agreed to be acquired by Merck.

Merck Adds HCV Candidates with Idenix Buy

Merck Adds HCV Candidates with Idenix Buy

Merck is making an all-cash $3.85 billion tender offer for Cambridge, Mass.-based Idenix Pharmaceuticals in a strategic bid to strengthen Merck's hepatitis C drug program.

Achillion Pharma Might be Next Hep C Takeout Target

Achillion Pharma Might be Next Hep C Takeout Target

Johnson & Johnson and Abbvie were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $TK Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target.

Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal

Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal

With Gilead Sciences already marketing the hepatitis C pill Sovaldi and competition from Abbvie-Enanta Pharma and Bristol-Myers Squibb close behind, a lot of investors believed the hepatitis C drug race had transitioned to marketing and away from M&A. But Merck chief scientitist Roger Perlmutter is no dummy, so his decision to spend almost $4 billion on Idenix says the hepatitis C treatment market may have a much longer tail than many believed.

Finding Good Picks Among 13Fs

I will explore Gannett because I love firms with many owned assets.

IDIX Crosses Above Key Moving Average Level

IDIX Crosses Above Key Moving Average Level

In trading on Wednesday, shares of Idenix Pharmaceuticals Inc crossed above their 200 day moving average of $5.42, changing hands as high as $5.52 per share. Idenix Pharmaceuticals Inc shares are currently trading up about 5.8% on the day.

Idenix Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for IDIX

Idenix Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for IDIX

In trading on Friday, shares of Idenix Pharmaceuticals Inc crossed below their 200 day moving average of $5.26, changing hands as low as $5.01 per share. Idenix Pharmaceuticals Inc shares are currently trading off about 6.8% on the day.

Idenix Pharmaceuticals is Now Oversold (IDIX)

Idenix Pharmaceuticals is Now Oversold (IDIX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of May 17th Options Trading For Idenix Pharmaceuticals (IDIX)

First Week Of May 17th Options Trading For Idenix Pharmaceuticals (IDIX)

Investors in Idenix Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IDIX options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

4 Stocks Under $10 to Trade for Breakouts

4 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences In Europe

Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences In Europe

Granted European Patent Covering 2'-Methyl-2'-Fluoro Nucleosides for Treating Hepatitis C Virus

The 10 Most Heavily Shorted Bio-Pharma Stocks

The 10 Most Heavily Shorted Bio-Pharma Stocks

The No. 1 stock on this list has more than half its float short.

Top Insider Trades: PSX YRCW CRTX IDIX

Top Insider Trades: PSX YRCW CRTX IDIX

The top 10 open-market insider purchases and sales filed at the SEC Tuesday.

Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised

Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised

Idenix is doubling down on hepatitis C drug development and litigation against Gilead Sciences, CEO Ron Renaud says.

Perilous Reversal Stock: Idenix Pharmaceuticals (IDIX)

Perilous Reversal Stock: Idenix Pharmaceuticals (IDIX)

Trade-Ideas LLC identified Idenix Pharmaceuticals (IDIX) as a "perilous reversal" (up big yesterday but down big today) candidate

The J.P. Morgan Healthcare Confab Monday Morning News Dump

The J.P. Morgan Healthcare Confab Monday Morning News Dump

It's still pre-dawn in San Francisco, a few hours from the start of the J.P. Morgan Healthcare Conference, but that hasn't stopped biotech and drug companies from dumping a ton of news and announcements into the market. Here's a brief look at what's making headlines this morning:

Market Hustle: Futures Rise Despite More China Weakness

Market Hustle: Futures Rise Despite More China Weakness

U.S. stock futures are pointing higher Monday as investors look for further signs of U.S. economic improvement.